| Multiple Myeloma
Mozobil vs Pomalyst
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Mozobil vs Pomalyst with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPomalyst has a higher rate of injection site reactions vs Mozobil based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Pomalyst but not Mozobil, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mozobil
Pomalyst
At A Glance
SC injection
Once daily for up to 4 days
CXCR4 antagonist
Oral
Once daily, Days 1-21 of 28-day cycles
Thalidomide analogue (immunomodulatory)
Indications
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Multiple Myeloma
- Kaposi Sarcoma
Dosing
Lymphoma, Non-Hodgkin, Multiple Myeloma 0.24 mg/kg SC (or 20 mg fixed dose for patients <=83 kg) once daily approximately 11 hours prior to apheresis for up to 4 consecutive days, following filgrastim 10 mcg/kg once daily for 4 days; maximum 40 mg/day.
Renal Impairment (CrCl <=50 mL/min) Reduce dose by one-third to 0.16 mg/kg SC (or 13 mg fixed dose for patients <=83 kg); maximum 27 mg/day.
Multiple Myeloma 4 mg once daily orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression; given in combination with dexamethasone.
Kaposi Sarcoma 5 mg once daily orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression or unacceptable toxicity; continue HAART as HIV treatment in patients with AIDS-related KS.
Contraindications
- History of hypersensitivity to plerixafor
- Pregnancy
- Severe hypersensitivity (e.g., angioedema, anaphylaxis) to pomalidomide or any excipient
Adverse Reactions
Most common (>=10%) Diarrhea, nausea, injection site reactions, fatigue, headache, arthralgia, dizziness, vomiting
Serious Anaphylactic shock, hypersensitivity reactions, tumor cell mobilization, hyperleukocytosis, decreased platelet counts, splenic enlargement
Postmarketing Splenomegaly, splenic rupture, anaphylactic reactions including anaphylactic shock, abnormal dreams and nightmares
Most common (>=10%) Neutropenia, anemia, fatigue/asthenia, constipation, nausea, diarrhea, dyspnea, upper respiratory tract infection, pneumonia, back pain, peripheral neuropathy, edema peripheral, pyrexia, thrombocytopenia, rash
Serious Venous and arterial thromboembolism, hematologic toxicity (neutropenia, thrombocytopenia, febrile neutropenia), hepatotoxicity, severe cutaneous reactions, pneumonia, sepsis, dizziness and confusional state, neuropathy, tumor lysis syndrome
Postmarketing Pancytopenia, hepatic failure, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, progressive multifocal leukoencephalopathy, hepatitis B virus reactivation, herpes zoster, tumor lysis syndrome, basal cell carcinoma, squamous cell carcinoma of the skin
Pharmacology
Plerixafor is a CXCR4 chemokine receptor inhibitor that blocks binding of stromal cell-derived factor-1alpha (SDF-1alpha), disrupting HSC anchoring in the bone marrow and mobilizing hematopoietic stem cells to the peripheral blood for apheresis collection.
Pomalidomide is a thalidomide analogue with immunomodulatory, antiangiogenic, and antineoplastic properties; it acts through cereblon (a cullin ring E3 ubiquitin ligase component), targeting substrate proteins Aiolos and Ikaros for ubiquitination and degradation, producing direct cytotoxic and immunomodulatory effects including enhanced T cell- and NK cell-mediated immunity and inhibition of pro-inflammatory cytokines (TNF-alpha and IL-6).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mozobil
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Pomalyst
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Mozobil
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Pomalyst
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Mozobil
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Pomalyst
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chemotherapy Induced Neutropenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MozobilView full Mozobil profile
PomalystView full Pomalyst profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.